强化血压控制与标准血压控制对心血管结局的影响:一项随机对照试验的系统评价和荟萃分析
Impact of Intensive Blood Pressure Control Versus Standard Control on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
作者信息
Rizwanullah Ufn, Vineesh Allenki, Hyderi Fardin Akbar, Shah Shivani, Sawale Mihika, Ahmadi Tahera, Kumar Makam Surendraiah Pavan, Kanduri Hanumantharayudu Sneha, Hussain Fazeel, Awasthi Chet Raj, Urbina Raul, Abifaraj Andrea
机构信息
Internal Medicine, Hayatabad Medical Complex Peshawar, Peshawar, PAK.
Community Medicine, Mallareddy Institute of Medical Sciences, Hyderabad, IND.
出版信息
Cureus. 2025 Jul 7;17(7):e87456. doi: 10.7759/cureus.87456. eCollection 2025 Jul.
Hypertension is one of the most frequent non-inherited risks to health that contributes to cardiovascular disease. Whereas the effects of reducing blood pressure are clear-cut, it is debatable what the optimal blood pressure level should be maintained. The objective of this systematic review and meta-analysis was to compare intensive blood pressure control with standard blood pressure control regarding cardiovascular outcomes, specifically focusing on major adverse cardiovascular events (MACE). We searched electronic databases comprehensively (PubMed, Embase, and Cochrane Library) from inception up to March 2025 to find randomized controlled trials comparing intensive control of systolic blood pressure with standard control. The primary outcome was MACE, a composite measure including all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, heart failure, and adverse events. Meta-analysis was performed using random effects to measure risk ratios (RRs) and 95% confidence intervals (CIs). Our analysis incorporated 37,249 subjects from 12 randomized controlled trials. Intensive blood pressure control significantly decreased the odds of MACE (RR: 0.80, 95% CI: 0.73-0.88) compared to standard management. Notable reductions were also observed in cardiovascular mortality (RR: 0.78, 95% CI: 0.67-0.90), stroke (RR: 0.78, 95% CI: 0.68-0.90), and heart failure (RR: 0.73, 95% CI: 0.61-0.88). However, intensive management was associated with higher risks of hypotension, syncope, electrolyte imbalance, and acute kidney injury. Overall, our results indicate that achieving lower blood pressure targets yields significant cardiovascular benefits, particularly in reducing MACE, cardiovascular mortality, stroke, and heart failure. However, these advantages must be weighed against the increased risk of adverse events. Treatment decisions should be individualized based on patient characteristics, risk factors, and preferences. Additionally, moderate heterogeneity was noted across studies, and the risk of bias was assessed, revealing good methodological quality overall.
高血压是导致心血管疾病的最常见非遗传性健康风险之一。虽然降低血压的效果是明确的,但关于应维持的最佳血压水平仍存在争议。本系统评价和荟萃分析的目的是比较强化血压控制与标准血压控制在心血管结局方面的差异,特别关注主要不良心血管事件(MACE)。我们全面检索了电子数据库(PubMed、Embase和Cochrane图书馆),从数据库建立至2025年3月,以查找比较收缩压强化控制与标准控制的随机对照试验。主要结局是MACE,这是一个综合指标,包括全因死亡率、心血管死亡率、心肌梗死、中风、心力衰竭和不良事件。使用随机效应模型进行荟萃分析,以测量风险比(RR)和95%置信区间(CI)。我们的分析纳入了12项随机对照试验中的37249名受试者。与标准管理相比,强化血压控制显著降低了发生MACE的几率(RR:0.80,95%CI:0.73-0.88)。在心血管死亡率(RR:0.78,95%CI:0.67-0.90)、中风(RR:0.78,95%CI:0.68-0.90)和心力衰竭(RR:0.73,95%CI:0.61-0.88)方面也观察到显著降低。然而,强化管理与低血压、晕厥、电解质失衡和急性肾损伤的较高风险相关。总体而言,我们的结果表明,实现更低的血压目标可带来显著的心血管益处,特别是在降低MACE、心血管死亡率、中风和心力衰竭方面。然而,这些优势必须与不良事件风险增加相权衡。治疗决策应根据患者特征、风险因素和偏好进行个体化。此外,各研究间存在中度异质性,并评估了偏倚风险,总体显示方法学质量良好。